but not NF-kB related genes in MoDCs of BP allergic donors. Healthy donors were either unresponsive or showed elevated mRNA levels of the Th1-promoting chemokines CXCL10 and CXCL11. Conclusions: This study supported by grant SFB-F1802 of the Austrian Science Fund shows for the first time that the allergen uptake is specific and similar in DCs from allergic and healthy individuals. More important, the ensuing signal cascade that is triggered by the allergen differs between DCs of the 2 donor groups and results in a Th2-polarized immune response in allergic individuals as compared to ignorance/tolerance in normal donor cells. 2 Allergy Clinic Reumannplatz, Vienna, Austria. Background: Parvalbumin, the major fish allergen, is responsible for IgE cross-reactivity among different fish species. We aimed to generate recombinant single chain antibody fragments (scFv) binding to epitopes responsible for IgE cross-reactivity among parvalbumins. Methods: The parvalbumin-specific scFvs were selected from the human synthetic scFv phage library ETH-2 by alternating the parvalbumin from cod (Gad m 1), carp (Cyp c 1) and trout (Onc m 1) during 3 rounds of sequential biopanning. Based on their reactivity to parvalbumins by ELISA, 2 clones were expressed in Escherichia coli. The ability of the 2 scFv antibodies to inhibit the binding of parvalbumin-specific IgE from fish allergic patients' sera was showed by ELISA competition experiments and the rat basophilic leukemia mediator release assay. Results: Based on ability to bind different parvalbumins and sequence analysis, phage clones scFv-gco9 and scFv-goo8 were selected for production of soluble scFv antibodies. We obtained 1 mg of scFv-gco9 and 1.3 mg of scFv-goo8 per litre of bacterial culture. The scFv-gco9 was able to detect all 3 parvalbumins at a concentration of 10 ng/mL. The scFv-goo8 bound to cod parvalbumin, but not to carp and trout parvalbumin. The detection limit for 1 mg/mL of the scFv-gco9 was 0.01 mg/mL of the Gad m 1 and 0.2 mg/mL of Onc m 1 or Cyp c 1. We found that scFv-gco9 dose-dependently blocked the binding of IgE to immobilized Gad m 1, Cyp c 1 and Onc m 1. At a concentration of 5 mg/mL of scFv-gco9 binding of IgE to the 3 parvalbumins was inhibited by approximately 40%, and at a concentration of 20 mg/mL the IgE binding was inhibited to w70%. In the case of the scFv-goo8, inhibition of IgE binding to Gad m 1 was about 15%. The inhibition of degranulation of basophils was 55% in the presence of 2 mg/mL scFv-gco9. Conclusions: This work, supported by grant SFB-F01802, revealed that the scFv antibodies can be used for the standardization of protein extracts used for allergy diagnosis and for IgE epitope mapping. Epitope characterization enables the engineering of parvalbumin molecules with reduced IgE binding for allergen-specific immunotherapy.
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2 Allergy Clinic Reumannplatz, Vienna, Austria. Background: Parvalbumin, the major fish allergen, is responsible for IgE cross-reactivity among different fish species. We aimed to generate recombinant single chain antibody fragments (scFv) binding to epitopes responsible for IgE cross-reactivity among parvalbumins. Methods: The parvalbumin-specific scFvs were selected from the human synthetic scFv phage library ETH-2 by alternating the parvalbumin from cod (Gad m 1), carp (Cyp c 1) and trout (Onc m 1) during 3 rounds of sequential biopanning. Based on their reactivity to parvalbumins by ELISA, 2 clones were expressed in Escherichia coli. The ability of the 2 scFv antibodies to inhibit the binding of parvalbumin-specific IgE from fish allergic patients' sera was showed by ELISA competition experiments and the rat basophilic leukemia mediator release assay. Results: Based on ability to bind different parvalbumins and sequence analysis, phage clones scFv-gco9 and scFv-goo8 were selected for production of soluble scFv antibodies. We obtained 1 mg of scFv-gco9 and 1.3 mg of scFv-goo8 per litre of bacterial culture. The scFv-gco9 was able to detect all 3 parvalbumins at a concentration of 10 ng/mL. The scFv-goo8 bound to cod parvalbumin, but not to carp and trout parvalbumin. The detection limit for 1 mg/mL of the scFv-gco9 was 0.01 mg/mL of the Gad m 1 and 0.2 mg/mL of Onc m 1 or Cyp c 1. We found that scFv-gco9 dose-dependently blocked the binding of IgE to immobilized Gad m 1, Cyp c 1 and Onc m 1. At a concentration of 5 mg/mL of scFv-gco9 binding of IgE to the 3 parvalbumins was inhibited by approximately 40%, and at a concentration of 20 mg/mL the IgE binding was inhibited to w70%. In the case of the scFv-goo8, inhibition of IgE binding to Gad m 1 was about 15%. The inhibition of degranulation of basophils was 55% in the presence of 2 mg/mL scFv-gco9. Conclusions: This work, supported by grant SFB-F01802, revealed that the scFv antibodies can be used for the standardization of protein extracts used for allergy diagnosis and for IgE epitope mapping. Epitope characterization enables the engineering of parvalbumin molecules with reduced IgE binding for allergen-specific immunotherapy. 2 Immune Tolerance Network, Washington, WA. Background: Grass pollen immunotherapy is associated with reduction in symptoms, the need for rescue medication and improvement of quality of life in patients with severe seasonal pollinosis. Although, the suppression of the early allergic response following in vivo cutaneous allergen challenge is associated with inhibition of basophil histamine release, the effects of immunotherapy on basophil reactivity is yet to be fully determined. We hypothesized that basophil reactivity as measured by increased expression of surface activation markers CD203c, CD63 and CD107a on CRTH21 basophils is increased in grass pollen allergic individuals following in vitro allergen stimulation. We further hypothesized that this hypereactivity is reduced in immunotherapy-treated patients. Methods: Heparinized blood obtained from grass pollen allergics (n ¼ 7), immunotherapy treated patients (n ¼ 6) and non-atopic controls (n ¼ 9) was incubated with 0, 0.1, 1, 10 and 100 ng/mL of P. Pratense extract at 378C for 15 minutes. Cells were stained with anti-CD3, CRTh2, CD123, CD303, CD203c, CD63 and CD107a. Additionally, whole blood basophil histamine release was measured pre/post immunotherapy by ELISA (n ¼ 6). Results: A dose-dependent increase in the proportion of CD203c1, CD631 and CD107a1 CRTH21 basophils was observed following in vitro grass pollen stimulation in allergics but not in non-atopic controls. At 100 ng/mL of P. Pratense extract, CD203c1, CD631 and CD107a1CRTH21 basophils were significantly elevated in allergics compare to non-topics (P , 0.001, P , 0.001 and P , 0.009). This increase in CD203c1, CD631CRTH21 basophils in allergic individuals significantly correlated with timothy-specific IgE (r ¼ 0.84, P , 0.0001; r ¼ 0.85, P , 0.0001). Interestingly, 10-to 100-fold more allergen was required for CRTH21 basophils to express CD203c, CD63 and CD107a in immunotherapy-treated patients compare to grass pollen allergics. At suboptimal allergen-concentration (10 ng/mL), CD203c1, CD631 and CD107a1CRTH21 basophils were significantly reduced in immunotherapy treated subjects compare to allergics (P , 0.001, P , 0.001 and P , 0.002). Basophil histamine release measured after treatment was significantly reduced compared to pre-treatment levels (P , 0.03). Conclusions: Basophil reactivity and histamine release is significantly reduced following grass pollen immunotherapy. The use of surface activation markers CD203c, CD63 and CD107a on basophils for monitoring clinical efficacy requires further investigations. Background: Allergoids were first used in the decades of the 60s and 70s of the last century as an effective treatment of allergic respiratory diseases. Allergoids can be modified with formaldehyde or glutaraldehyde. Modified allergens, or allergoids, decrease the risk of adverse reactions while administering higher allergen doses. The objective of this study was to analyse specific IgE and IgG binding to glutaraldehyde modified and non-modified allergen extracts of Phleum pratense. Methods: The sera of 69 patients sensitized to P. pratense were tested. All these patients had signs and symptoms of rhinoconjunctivitis with, or without, asthma in May and June of 2011. All these patients had positive skin prick tests to a standardized extract of P. pratense, and other grass species. Most patients were also sensitized to olive pollen. Specific IgE and IgG binding were analysed by direct ELISA against P. pratense native (non-modified) and allergoid extracts. Relative potencies were evaluated through ELISA inhibition assays, and the protein composition of non-modified and allergoid samples was determined by Mass Spectrometry (MS/MS). Results: Mean Specific IgE levels against the native extract was 16.68 6 11.65 Units (U) and against the allergoid: 7.26 6 8.24 U (P , 0.0001; Mann-Whitney). On the other hand, mean specific IgG binding against the 
